Clinical significance of protocadherin 8 PCDH8 promoter methylation in non-muscle invasive bladder cancerReport as inadecuate




Clinical significance of protocadherin 8 PCDH8 promoter methylation in non-muscle invasive bladder cancer - Download this document for free, or read online. Document in PDF available to download.

Journal of Experimental and Clinical Cancer Research

, 33:68

First Online: 22 August 2014Received: 14 June 2014Accepted: 12 August 2014DOI: 10.1186-s13046-014-0068-7

Cite this article as: Lin, YL., Wang, YL., Ma, JG. et al. J Exp Clin Cancer Res 2014 33: 68. doi:10.1186-s13046-014-0068-7

Abstract

BackgroundPCDH8 is a novel tumor suppressor gene, and frequently inactivated by promoter methylation in human cancers. However, there is little information regarding PCDH8 methylation in non-muscle invasive bladder cancer NMIBC. The aim of this study was to investigate the methylation status of PCDH8 in NMIBC and its clinical significance.

MethodsThe methylation status of PCDH8 in 233 NMIBC tissues and 43 normal bladder epithelial tissues was examined by methylation-specific PCR MSP, and then analyzed the correlations between PCDH8 methylation and clinicopatholocial features. Subsequently, Kaplan-Meier survival analysis and Multivariate Cox proportional hazard model analysis was used to investigate the correlation between PCDH8 methylation and prognosis of patients with NMIBC.

ResultsPCDH8 methylation occurred frequently in NMIBC tissues than those in normal bladder epithelial tissues. In addition, PCDH8 methylation significantly correlated with advanced stage, high grade, larger tumor size, tumor recurrence and progression in NMIBC. Kaplan-Meier survival analysis revealed that patients with PCDH8 methylated have shorter recurrence-free survival, progression-free survival and five-year overall survival than patients with PCDH8 unmethylated. Multivariate analysis suggested that PCDH8 methylation was an independent prognostic biomarker for recurrence-free survival, progression-free survival and five-year overall survival simultaneously.

ConclusionsPCDH8 methylation may be associated with tumor progression and poor prognosis in NMIBC and may be used as a potential biomarker to predict the prognosis of patients with NMIBC.

KeywordsBladder cancer Methylation PCDH8 Protocadherin-8 Biomarker Electronic supplementary materialThe online version of this article doi:10.1186-s13046-014-0068-7 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Author: Ying-Li Lin - Yan-Ling Wang - Jian-Guo Ma - Wen-Ping Li

Source: https://link.springer.com/







Related documents